Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 3652703 trials

curacle co., ltd.

Official website

Curacle is a KOSDAQ-listed biotech venture developing therapeutics that normalize endothelial dysfunction via its SOLVADYS and EAGLES discovery platforms.

As of 2026-10-10, curacle co., ltd. has 21 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2016 and listed on KOSDAQ in 2021, Curacle Co., Ltd. is a biotech venture developing therapeutics that normalize endothelial dysfunction to treat intractable diseases. Using its small-molecule discovery platform SOLVADYS® and biologics discovery platform EAGLES®, the company is advancing pipelines including Rivasterat (CU06), CU71, and CU01, with Rivasterat, a retinal disease candidate for diabetic macular edema, having completed a U.S. Phase 2a trial. In 2021 Curacle out-licensed Rivasterat to France's Thea Open Innovation in a deal worth up to US$163.5 million, though the agreement was terminated in 2024, while its kidney disease candidate CU01 completed a domestic Phase 2b trial in 240 patients with last-subject-out in November 2025.

Clinical trials

data.go.kr

3 MFDS clinical trial authorisations · 2019–2022 (Phase 2a 2 · Phase 2b 1)

  • Phase 2bCU01-10012022-07-06

    24 trial sites

  • Phase 2aCU03-1001정2019-12-04

    8 trial sites

  • Phase 2aCU01-10012019-05-08

    7 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

Rivasterat(CU06) · 당뇨병성 황반부종 및 습성 황반변성 · 미국 임상2a상 완료, 임상2b상 IND 신청 준비중 · ED Blocker discovered via the SOLVADYS® platform. Completed a U.S. Phase 1 trial in June 2022 and a U.S. Phase 2a trial in April 2024; targeting an IND filing for Phase 2b in H1 2026.

CU71 · 알츠하이머병, 혈관성 치매 등 퇴행성 뇌질환 · 전임상 · A BBB stabilizer discovered via the SOLVADYS platform and SPAR concept. A composition-of-matter patent was filed in July 2024, and cognitive improvement was observed in an Alzheimer's animal model preclinical study.

CU01 · 당뇨병성 신증 · 국내 임상2b상 · Dual mechanism activating Nrf2 and inhibiting TGF-β signaling. A domestic Phase 2b trial in 240 patients was approved in July 2022, with last-subject-out in November 2025 and a Topline CSR draft expected in January 2026.

MT-101, MT-102, MT-103, MT-104 등 항체 파이프라인 · 전임상 · Part of eight antibody pipelines secured through a joint R&D agreement signed with antibody specialist Maptics in July 2024; currently in preclinical stage.

Key disclosures

KRX KIND via OpenDART
Show 1 more events

Publications

PubMed · affiliation-matched
Show 11 more publications

Patents

KIPRIS · applicant-matched
Show 33 more patents

AI reads

MAA server logs · IP-verified
70
Times AI engines pulled curacle co., ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

5
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

65
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 3
Last 7 days
59
live 5
Last 30 days
70
live 5
All time
  • OpenAIChatGPT-Userlive5
  • OpenAIOAI-SearchBot59
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for curacle co., ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition